Abivax (ABVX) Current Deferred Revenue (2023)

Abivax (ABVX) posted quarterly Current Deferred Revenue of $55948.9 for Q4 2023.

Abivax (ABVX) Current Deferred Revenue (2023) Analysis & Trends

Abivax's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $55948.9 for Q4 2023.

In Q4 2023, Current Deferred Revenue changed N/A year-over-year to $55948.9; the TTM figure through Dec 2023 stood at $55948.9 (changed N/A YoY), while the FY2023 annual figure was $55948.9, changed N/A from the prior year.
Current Deferred Revenue for Q4 2023 stood at $55948.9.
The five-year high for Current Deferred Revenue was $55948.9 in Q4 2023, with the low at $55948.9 in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Abivax	9.39 Bn	9.39 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2023	55,948.88